Gingko Bioworks secures $275 million in Series D, valuing the company at over $1 billion

 Boston biotech startup Gingko Bioworks has announced the raise of $275 million in Series D funding to build out its Bioworks3 production facility. The funding comes from previous investors Viking Global, Y Combinator’s Continuity Fund, Cascade Investment, Bill Gates, as well as new investor, General Atlantic. The company previously raised over $154 million, bringing the total up to… Read More

from Startups – TechCrunch http://ift.tt/2ksn4Ym
via IFTTT